Accumulating evidence has confirmed the prognostic impact of TILs in NSCLC patients, clarifying that increased levels of CD3 and CD8+ TILs are associated with better outcomes in NSCLC [37,38,39]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.